Open AccessPredictive factors of the tumor immunological microenvironment for long‐term follow‐up in early stage breast cancer
Author(s) -
Okabe Mina,
Toh Uhi,
Iwakuma Nobutaka,
Saku Shuko,
Akashi Momoko,
Kimitsuki Yuko,
Seki Naoko,
Kawahara Akihiko,
Ogo Etsuyo,
Itoh Kyogo,
Akagi Yoshito
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13114
Subject(s) - pten , tensin , breast cancer , immunohistochemistry , medicine , stage (stratigraphy) , cancer , tumor microenvironment , oncology , triple negative breast cancer , cancer research , pathology , biology , pi3k/akt/mtor pathway , apoptosis , paleontology , biochemistry
The aim of this research was to investigate the correlation of immunologic factors in the tumor environment of breast cancer, using immunohistological staining to evaluate the expression of programmed death 1/programmed death ligand 1 ( PD ‐1/ PD ‐L1), phosphatase and tensin homolog ( PTEN ), tumor infiltrating lymphocytes ( TIL s), and macrophages, and to analyze the association between the immunologic factors and clinical outcome for patients with early stage breast cancer ( EBC ). A total of 97 EBC patients who underwent standard surgery were investigated. Expression of PD ‐1/ PD ‐L1 and PTEN and the density of CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages were evaluated by immunohistochemical analysis. The association between the immunologic factors and clinical outcome was statistically analyzed. The density of CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages and non‐expression of PTEN was significantly higher in cases of triple negative breast cancer. CD 8 + TIL density and CD 8 + / PD ‐L1 + expression were predictive factors for disease‐free survival and overall survival ( OS ). Human epidermal growth factor 2 ( HER 2)‐positive patients with PTEN expression and luminal/ HER 2‐negative patients without PD ‐L1 expression had significantly longer OS compared to patients without PTEN expression ( P = 0.049) and with PD ‐L1 expression ( P = 0.036), respectively. Furthermore, patients with PD ‐L1 + / CD 8 + expression had worse median progression‐free survival ( P = 0.022) and median OS ( P = 0.037) compared with patients without PD ‐L1 + / CD 8 + expression. The CD 3 + TIL s, CD 8 + TIL s, and CD 163 + macrophages were shown to infiltrate the tumor area of EBC . In particular, triple negative breast cancer had a higher rate of TIL infiltration within the tumor environment. Expression of PTEN and lack of PD ‐L1 expression were associated with favorable survival in HER 2‐positive and luminal/ HER 2‐negative EBC patients, respectively. The PD ‐L1 expression combined with CD 8 + density was significantly associated with an aggressive clinical outcome.